This enzyme belongs to the KDM5 subfamily, which was found to be upregulated in prostate cancer patients [75] and to be frequently mutated in pediatric AML specimens [76] as well as in human MM cell lines [77], supporting the idea of KDM5C functioning as an oncogenic driver [78]. The gene discussed is KDM5C; the disease is Miyoshi myopathy.